LOVELAND, Colo., Dec. 14, 2011 /PRNewswire/ -- Heska Corporation (NASDAQ: HSKA; "Heska"), a leading provider of advanced diagnostic and specialty products to veterinarians, announced today the intent to collaborate with Entegrion Inc., a company with core expertise in blood-related disorders. The parties are to explore unique technologies in the areas of coagulation and blood cell-based therapeutics, for use in the veterinary market.
"Heska is pleased to announce this strategic initiative into an exciting frontier in medicine, and expand our product and service offerings," commented Michael McGinley, President and Chief Operating Officer of Heska. "As part of Heska's stated commitment to growth, focused on the introduction of innovative and competitively differentiated products, we seek to work with innovative leaders in the life science sector. Entegrion is just such an innovator, sharing a parallel path with us in advancing healthcare – Heska committed to advancing animal health, and Entegrion committed to identifying and developing new technologies for human medical needs. We expect this collaboration will lead to the development of products that advance our mutual goals."
Joseph DaCorta, Vice President and Chief Technology Officer for Entegrion Inc., stated "Entegrion is pleased to join forces with Heska, a veterinary industry leader, dedicated to perfecting and supporting quality pet care and whose pursuit of innovation directly matches Entegrion's values and focus on meeting unmet health needs."
Heska Corporation (NASDAQ: HSKA) sells advanced veterinary diagnostic and other specialty veterinary products. Heska's state-of-the-art offerings to its customers include diagnostic and monitoring instruments and supplies as well as single use, point-of-care tests, vaccines and pharmaceuticals. The company's core focus is on the canine and feline markets where it strives to provide high value products and unparalleled customer support to veterinarians. For further information on Heska and its products, visit the company's website at www.heska.com.
Entegrion is a life sciences development company that is focused on improving the safety and availability of the world's blood supply. Based in North Carolina's Research Triangle Park, Entegrion offers patented technologies designed to overcome limitations in storage, safety, and availability of blood-derived products while preserving their functionality. Many of Entegrion's advances in biologics are based on close collaborations with leading medical research institutions. Visit http://www.entegrion.com for more information.
This announcement contains forward-looking statements regarding Heska's future financial and operating results. These statements are based on current expectations and are subject to a number of risks and uncertainties including risks related to Heska's reliance on a third party, Entegrion Inc., to collaborate and deliver specific products of interest. There are uncertainties regarding Heska and Entegrion's ability to successfully commercialize new products; uncertainties regarding Heska's ability to market, sell and distribute products; uncertainties regarding the performance of any new products in field use; uncertainties regarding the outcome of any collaborations between Heska and any third party, including Entegrion; risks related to relying on the reputation of Heska, Entegrion or any other entity, which is subject to interpretation and may change over time; uncertainties related to the future development efforts of any third party; competition; and the risks set forth in Heska's filings and future filings with the Securities and Exchange Commission, including those set forth in Heska's Annual Report on Form 10-Q for the quarter ended September 30, 2011.
|SOURCE Heska Corporation|
Copyright©2010 PR Newswire.
All rights reserved